证券代码：300253 证券简称：卫宁健康 公告编号：2024-041 卫宁健康科技集团股份有限公司 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2024 年 4 月 19 日在巨潮资讯网上发布了《关于召开 2023 年度股东大会的通 知》。本次会议将采取现场投票与网络投票相结合的方式进行，现将 会议有关事项提示如下： 一、召开会议的基本情况 1、股东大会届次：2023 年度股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：公司第六届董事会第二次会议审 议通过了《关于提请召开公司 2023 年度股东大会的议案》。本次股东 大会会议的召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》等规定。 关于召开 2023 年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 （1）现场会议时间：2024 年 5 月 10 日（星期五）14:30 （2）网络投票时间：2024 年 5 月 10 日，其中： ①通过深圳证券交易所交易系统进行网络投票的具体时间为： 2024 年 5 月 10 日 9:15-9:25， ...

注：专利权期限为二十年，自申请日起算。 上述发明专利是一项已经用在产品研发过程中的测试方法的专 利。上述发明专利的取得不会对公司近期经营产生重大影响，但有利 于公司进一步完善知识产权保护体系，发挥自主知识产权优势，提升 公司的核心竞争力。 证券代码：300253 证券简称：卫宁健康 公告编号：2024-040 卫宁健康科技集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）近日取得 由国家知识产权局颁发的一项发明专利证书。具体情况如下： | 专利名称 | 专利号 | 专利申 | | 专利 | 摘要 | | --- | --- | --- | --- | --- | --- | | | | 请日 | | 权人 | | | | | | | | 本申请提供一种测试用例自动生成方法、装置、 | | | | | | | 电子设备及存储介质，涉及测试技术领域。该 | | | | | | | 方法包括：确定输入的测试需求的目标需求分 | | | | | | 卫 宁 | 析类型，确定测试 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a current price of 6.94 CNY and a reasonable value of 8.49 CNY, corresponding to a 35x PE for 2024 [7][30]. Core Insights - The company reported a strong performance in Q1 2024, achieving revenue of 490 million CNY, a year-on-year increase of 10.1%, and a net profit of 16.62 million CNY, reversing a loss of 63.53 million CNY in the same period last year [2][30]. - The company is entering a phase of mass promotion for its WiNEX system in 2024, having successfully onboarded several benchmark clients, which is expected to enhance delivery efficiency [6]. - The company is actively advancing its Internet healthcare business and has made significant progress in the AI+ healthcare sector, launching WiNGPT and integrating it into its products [6]. Financial Summary - Revenue is projected to grow from 3.63 billion CNY in 2024 to 4.74 billion CNY in 2026, with corresponding net profits of 524 million CNY and 821 million CNY respectively [3][30]. - The company’s gross margin for Q1 2024 was 33.7%, an increase of 1.28 percentage points from Q1 2023, while the sales expense ratio decreased by 11.49 percentage points to 15.1% [2]. - The company’s earnings per share (EPS) are expected to rise from 0.24 CNY in 2024 to 0.38 CNY in 2026, reflecting a strong growth trajectory [6][30].

[Table_Title] 盈利能力显著回升，WiNEX 产品推广顺利 2023 年营业收入实现稳健增长，盈利能力显著回升 2023 年，公司研发投入达 6.97 亿元，同比增长 11.47%，占营业收入的比 例为 22.04%。公司积极推动以大模型为代表的新质生产力在医疗领域落 地。2023 年 1 月，公司启动医疗垂直领域大模型的研发工作；10 月，正式 发布医疗垂直领域大模型 WiNGPT，并以医护智能助手 WiNEX Copilot 的 形态内置于全系列产品中。WiNEX Copilot 致力于成为医护好帮手，已集成 涵盖医院管理、医生增效以及患者端等 100 多个临床应用场景，为医护人 员提供全面的智能知识服务。年内，WiNEX Copilot 病历文书助手、影像报 告助手等智能应用已在北京、上海等地的头部医院推进落地，在医疗领域大 模型应用方面形成了比较优势。 盈利预测与投资建议 技术与产品开发风险；行业竞争进一步加剧的风险；公司规模扩张带来的管 理风险；人才流失风险；收款及经营业绩的季节性波动风险；商誉减值风险。 | --- | --- | |-------------------------- ...

Investment Rating - The report maintains a "Recommended" rating for the company, with an expected target price of 8.16 CNY based on a 34x PE for 2024 [27][28]. Core Insights - The company reported a revenue of 3.163 billion CNY for 2023, a year-on-year increase of 2.28%. The net profit attributable to shareholders reached 358 million CNY, showing a significant growth of 229.49% year-on-year. For Q1 2024, revenue was 494 million CNY, up 10.09% year-on-year, with a net profit of 17 million CNY, reflecting a 126.17% increase [14][28]. - The company's profit growth is notable, with a clear improvement in profitability. Despite external factors affecting industry order releases, the company has focused on business development and optimized its organizational structure, resulting in a 1.5 percentage point decrease in sales expense ratio in 2023 [28]. - The WiNEX product line is accelerating its rollout, contributing to the digital transformation of hospitals. By the end of 2023, the company expanded its WiNEX customer base significantly, including major hospitals and private medical institutions [28]. - The company launched the WiNGPT model in October 2023, integrating it into all product lines as the WiNEX Copilot, enhancing operational efficiency and quality of care across various clinical applications [28]. Financial Summary - For 2023, the company achieved total revenue of 3.163 billion CNY, with a projected revenue growth of 18.2% in 2024, reaching 3.739 billion CNY. The net profit is expected to grow to 512 million CNY in 2024, representing a 43% increase [15][28]. - The company's earnings per share (EPS) is projected to increase from 0.17 CNY in 2023 to 0.24 CNY in 2024, with a PE ratio decreasing from 42 to 30 over the same period [15][28]. - The total assets are expected to grow from 8.549 billion CNY in 2023 to 9.343 billion CNY in 2024, indicating a healthy financial outlook [29].

2024 年 04 月 27 日 公司研究 评级：买入(维持) [Table_Title] "1+X"战略深化，业绩趋势向好 事件: 2024Q1 毛利率同比提升，全年盈利能力有望持续恢复 当前价格（元） 6.94 总市值（百万） 14,982.93 公司深化推进"1+X"战略，2023 年，公司医疗卫生信息化、互联 网医疗健康业务收入分别为 28.49 亿元、3.12 亿元，分别同比+12.66%、 -44.53%，分业务看： 流通市值（百万） 12,909.48 总股本（万股） 215,892.31 相关报告 证券研究报告 公司积极推动"大模型+医疗"应用探索。2023 年 10 月，公司正式 发布医疗垂直领域大模型 WiNGPT，并以医护智能助手 WiNEX Copilot 的形态内置于公司全系列产品中。WiNEX Copilot 已集成涵盖医院管理、 医生增效以及患者端等 100 多个临床应用场景，提升医护工作效率、提 高医疗质量。2023 年，WiNEX Copilot 病历文书助手、影像报告助手等 智能应用已在北京、上海等地的头部医院推进落地。 流通股本（万股） 186,015.52 研究所： 证 ...

[Table_Summary 事件：公司发布] 2023年年度报告，实现营业收入 31.6亿元，同比增长 2.3%； 实现归母净利润 3.6亿元，同比增长 229.5%；实现扣非归母净利润 3.3亿元， 同比增长 178.5%。 医卫信息化收入稳健增长，人效提升利润恢复亮眼。 1）医卫信息化业务：2023 年实现收入 28.5亿元，同比增长 12.7%，其中核心产品软件销售及技术服务实 现收入 23.7亿元，同比增长 14.6%。虽然客观因素对行业订单释放产生一定影 响，公司医疗卫生信息化业务新签订单合同额同比仍然呈现增长趋势。2）互联 网医疗业务：2023年实现收入 3.1亿元，同比下滑 44.5%，其中卫宁科技新签 合同金额达到 2.7亿元，同比增长 122%。公司互联网医疗业务仍处于销售拓展、 研发投入阶段，但积极进行战略调整，亏损同比减少 44.6%。此外，报告期内 公司进行人员优化调整，2023 年人均创收 50.6 万元，同比提升 12.8%；综合 毛利率达到 45.0%，同比提升1.31pp，期间费用率达到32.9%，同比减少1.46pp， 助推盈利能力快速恢复。 "1+X"战略升级推进，WiN ...

证券代码：300253 证券简称：卫宁健康 公告编号：2024-038 卫宁健康科技集团股份有限公司 第六届监事会第三次会议决议公告 经审议，监事会认为：董事会编制和审核公司 2024 年第一季度 报告的程序符合法律、行政法规和中国证监会的规定，报告内容真实、 准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性 陈述或者重大遗漏。 《2024 年第一季度报告》详见中国证监会指定的创业板信息披 露网站。 特此公告。 本公司及监事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日在公司会议室以现场方式召开第六届监事会第三次会议。 会议通知于 2024 年 4 月 22 日以专人送达及电子邮件方式发出。会议 应出席监事 3 人，实际出席监事 3 人。会议由监事会主席李琳主持。 本次监事会的召集和召开符合《中华人民共和国公司法》和《公司章 程》的规定。经全体监事表决，形成决议如下： 会议以 3 票同意、0 票反对、0 票弃权的结果审议通过了《关于< 公司 2024 年第一季度报告>的议案》。 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2024-037 本议案在提交董事会审议前已经公司第六届董事会审计委员会 第三次会议审议并取得了全体同意的审查意见。 《2024 年第一季度报告》详见中国证监会指定的创业板信息披 露网站。 特此公告。 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日在公司会议室以现场和通讯相结合的表决方式召开了第 六届董事会第三次会议。会议通知于 2024 年 4 月 22 日以专人送达或 电子邮件方式发出。会议应出席董事 7 人，实际出席董事 7 人。本次 董事会的召集和召开符合《中华人民共和国公司法》和《公司章程》 的规定。会议由董事长周炜主持，公司监事及高级管理人员列席了本 次董事会。经全体董事表决，形成决议如下： 会议以 7 票同意、0 票反对、0 票弃权的结果审议通过了《关于< 公司 2024 年第一季度报告>的议案》。 卫宁健康科技集团股份有限公司 卫宁健康科技集团股份有限公司 董 事 会 二〇二四 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 494,492,405.71, representing a 10.09% increase compared to CNY 449,172,857.10 in the same period last year[9] - Net profit attributable to shareholders was CNY 16,620,407.26, a significant turnaround from a loss of CNY 63,534,739.90, marking a 126.16% increase[9] - The net profit after deducting non-recurring gains and losses was CNY 8,687,732.19, improving by 111.74% from a loss of CNY 74,028,076.85 in the previous year[9] - Basic earnings per share increased to CNY 0.0077 from a loss of CNY 0.0296, reflecting a 126.01% improvement[9] - The company achieved operating revenue of 494.49 million yuan, a year-on-year increase of 10.09%[45] - Net profit attributable to shareholders reached 16.62 million yuan, up 126.16% year-on-year[45] - The core business of healthcare information technology generated revenue accounting for 89.87% of total revenue, with a year-on-year growth of 16.81%[45] - The total comprehensive income for the current period is 6,494,450.04, compared to -90,204,109.26 in the previous period[60] Cash Flow and Assets - The company's cash flow from operating activities showed a net outflow of CNY 108,888,969.06, worsening by 18.32% compared to CNY 92,026,081.61 in the same period last year[9] - As of March 31, 2024, the company's cash and cash equivalents amounted to CNY 973.09 million, down from CNY 1.114 billion at the beginning of the period[28] - The total current assets as of March 31, 2024, were CNY 4.746 billion, slightly down from CNY 4.854 billion at the beginning of the period[28] - The total cash and cash equivalents at the end of the period is 904,104,252.84, down from 990,968,902.14 in the previous period[62] Liabilities and Equity - The total liabilities decreased to CNY 2,716,898,318.12 from CNY 2,867,668,499.40, reflecting a reduction of about 5.3%[52] - The total equity attributable to shareholders increased to CNY 5,761,421,811.75 from CNY 5,687,089,041.72, an increase of approximately 1.3%[52] Shareholder Information - The number of shareholders at the end of the reporting period was 77,341, with the largest shareholder holding 8.17% of the shares[17] - The company’s total shares held by the top 10 shareholders accounted for 19.63% of the total share capital[39] - The total number of restricted shares at the end of the period was 298,767,886 shares[44] Operational Efficiency - The company recorded a 37.56% decrease in selling expenses, primarily due to reduced personnel costs during the reporting period[14] - Non-operating income decreased by 99.49%, mainly due to a reduction in income not directly related to regular business activities[14] - The company experienced a significant reduction in credit impairment losses and asset impairment losses, decreasing by over 200% due to increased cash collections[37] Investment and Projects - The company utilized CNY 14.1372 million of the raised funds for the "WiNEX MY project," with a cumulative usage of CNY 151.5781 million, achieving a usage progress of 79.08%[25] - The company confirmed government subsidies totaling CNY 26.1561 million, accounting for approximately 7.31% of the audited net profit attributable to shareholders for 2023[27] Revenue Breakdown - Revenue from software sales and technical services accounted for 72.04% of total revenue, growing by 14.89% year-on-year[45] - Revenue from hardware sales represented 17.83% of total revenue, with a year-on-year increase of 25.24%[45] - Internet healthcare revenue accounted for 10.13% of total revenue, showing a decline of 27.10% year-on-year[45] Share Issuance and Corporate Governance - The company issued 6,614,595 new shares as part of its stock option incentive plan during the reporting period[27] - The company completed the election of the sixth board of directors and supervisory board on March 21, 2024[25]